Hatchery International

News & Views Business Management
AquaBioTech looks toward international expansion with Bluefront Equity investment


October 7, 2021
By Hatchery International Staff

Topics
From the left: George Mantas (AquaBioTech Group business development director), Kjetil Haga (Bluefront Equity founding partner), Jan Sverre Røsstad (Bluefront Equity founding partner), Shane Hunter (AquaBioTech Group CEO), Alf-Helge Aarskog (Bluefront Equity founding partner), Robert Davies (AquaBioTech Group principal aquaculture consultant). Photo: AquaBioTech Group

AquaBioTech Group and Bluefront Equity have announced they have jointly entered into a letter of intent, stating Bluefront Equity will acquire a significant stake in AquaBioTech Group through a combination of purchase of shares, and new capital to accelerate the company’s growth. This investment will further enable AquaBioTech Group to quickly develop its international plans for expansion, including opening major offices in Norway and Singapore.

AquaBioTech Group consists of three main divisions. The first division’s facility is focused on aquaculture, fisheries, and marine environment consulting, advisory and training.

The second division is the Contract Research Organisation (CRO), which consists of more than 50 research recirculating aquaculture system (RAS) units in operation. This division’s facility is used by all major vetriceutical, nutraveutical and aquatic nutrition companies for aquatic vaccines and shrimp/fish feeds testing, development, and certification.

The final division is focused on the engineering and development of RAS turnkey supply for commercial and research focuses, designed for various fish and shrimp species. This includes salmon hatcheries, nurseries, and grow-out facilities.

Advertisement